Phibro Animal Health Corporation (PAHC) EPS Estimated At $0.44

August 13, 2018 - By Jack Shaw

Investors sentiment decreased to 1.32 in Q1 2018. Its down 0.09, from 1.41 in 2017Q4. It dived, as 9 investors sold Phibro Animal Health Corporation shares while 53 reduced holdings. 26 funds opened positions while 56 raised stakes. 18.04 million shares or 5.73% less from 19.14 million shares in 2017Q4 were reported.
28,600 were reported by Bessemer. Engineers Gate Manager Limited Partnership reported 0.04% in Phibro Animal Health Corporation (NASDAQ:PAHC). American Group Inc reported 12,631 shares. Rhumbline Advisers reported 0% in Phibro Animal Health Corporation (NASDAQ:PAHC). Envestnet Asset Mngmt Inc owns 3,150 shares. Stone Ridge Asset Management Limited Com stated it has 17,046 shares or 0.04% of all its holdings. Ny State Teachers Retirement System has 13,065 shares. First Manhattan holds 0% or 3,000 shares. Strs Ohio holds 0% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC) for 20,400 shares. Foundry Prns Limited Liability stated it has 63,260 shares or 0.11% of all its holdings. Manufacturers Life Insurance The holds 0% in Phibro Animal Health Corporation (NASDAQ:PAHC) or 15,591 shares. Us Bancorp De owns 1,229 shares for 0% of their portfolio. Barclays Public Limited Co invested in 0% or 6,059 shares. Natl Bank Of Montreal Can owns 69,935 shares. Eqis Cap Mngmt Inc holds 0.02% or 10,142 shares.

Since February 9, 2018, it had 0 insider buys, and 29 insider sales for $28.07 million activity. On Friday, March 23 BFI Co. – LLC sold $117,239 worth of Phibro Animal Health Corporation (NASDAQ:PAHC) or 2,600 shares. Bendheim Daniel M had sold 3,960 shares worth $158,647 on Monday, March 5. 10,000 shares were sold by Warras Dean J, worth $356,200. On Friday, February 9 Miller Larry Lee sold $1.93M worth of Phibro Animal Health Corporation (NASDAQ:PAHC) or 54,572 shares.

Analysts expect Phibro Animal Health Corporation (NASDAQ:PAHC) to report $0.44 EPS on August, 27 after the close.They anticipate $0.05 EPS change or 12.82 % from last quarter’s $0.39 EPS. PAHC’s profit would be $17.74M giving it 27.87 P/E if the $0.44 EPS is correct. After having $0.46 EPS previously, Phibro Animal Health Corporation’s analysts see -4.35 % EPS growth. The stock decreased 0.20% or $0.1 during the last trading session, reaching $49.05. About 53,006 shares traded. Phibro Animal Health Corporation (NASDAQ:PAHC) has risen 28.06% since August 13, 2017 and is uptrending. It has outperformed by 15.49% the S&P500.

Phibro Animal Health Corporation (NASDAQ:PAHC) Ratings Coverage

Among 2 analysts covering Phibro Animal Health (NASDAQ:PAHC), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Phibro Animal Health had 2 analyst reports since May 9, 2018 according to SRatingsIntel. The stock of Phibro Animal Health Corporation (NASDAQ:PAHC) has “Underweight” rating given on Thursday, July 5 by Barclays Capital. Credit Suisse maintained Phibro Animal Health Corporation (NASDAQ:PAHC) rating on Wednesday, May 9. Credit Suisse has “Neutral” rating and $42 target.

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition firm primarily in the United States. The company has market cap of $1.98 billion. It operates through three divisions: Animal Health, Mineral Nutrition, and Performance Products. It has a 34.06 P/E ratio. The firm develops, makes, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

More news for Phibro Animal Health Corporation (NASDAQ:PAHC) were recently published by:, which released: “Analysis: Positioning to Benefit within BioTelemetry, Genworth Financial, Power Integrations, Phibro Animal Health …” on August 06, 2018.‘s article titled: “Phibro Animal Health Corporation Declares Quarterly Dividend” and published on July 30, 2018 is yet another important article.

Phibro Animal Health Corporation (NASDAQ:PAHC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.